Cancer

New blood test may someday help guide the best treatment for aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Research in a small group of men with advanced prostate cancer found that a blood test that screens for a certain genetic mutation could help decide which of two types of drugs would be more likely to provide a longer lifespan.

Exercise as part of cancer treatment

Monique Tello, MD, MPH

Contributing Editor

Based on analyses of multiple studies showing benefits of exercise, Australia’s national cancer organization has issued formal guidelines recommending exercise as part of cancer treatment for all cancer patients. The guidelines emphasize that exercise recommendations be tailored to each patient.

Chondroitin and melanoma: How worried should you be?

Robert H. Shmerling, MD

Faculty Editor, Harvard Health Publishing

Research in mice found that the supplement chondroitin sulfate led to the growth of melanoma cells, and though this does not mean it will do the same in people, there isn’t much evidence to support taking chondroitin anyway.

4 ways to protect against skin cancer (other than sunscreen)

While sunscreen is essential for skin protection when spending time outdoors, there are other options (lifestyle modifications and over-the-counter products) that can help lower your risk of skin cancer.

New study once again casts doubt on PSA screening

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The largest study to date of prostate cancer screening reinforces the existing evidence that the potential benefits of the test are outweighed by the harms of overtreatment for low-grade cancer that could be left untreated.

A mix of treatments may extend life for men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Combining multiple forms of radiation therapy with hormone treatments lengthens survival in men with aggressive prostate cancer.

When dying is a rebirth

Linnea Olson

Guest Contributor

Almost a decade ago, after exhausting treatment options for lung cancer, Linnea Olson was given only a few months to live. But her participation in an early clinical trial — targeting a then newly identified mutation associated with lung cancer — produced an amazing response. Living with what remains a terminal illness, Linnea is embracing new personal goals, experiencing a creative renewal, and appreciating every moment.

FDA approves new drug for men at high risk of prostate cancer spread

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men whose PSA levels continue rising even after surgery or radiation therapy may have a new treatment option with the approval of the drug apalutamide.

Knowing when to screen… and when to quit

Robert H. Shmerling, MD

Faculty Editor, Harvard Health Publishing

Medical screening tests can help detect problems before they become hard to treat. Many screening tests are recommended for adults or when a person has certain risk factors. But when should screening stop? A new study examines this issue for colonoscopies.

Newer drugs are improving survival for men with metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.